retatrutide clinical trials status Phase 3: TRIUMPH Program Results 2026 retatrutide clinical trial status retatrutide

Food and Drug Administration (FDA) for human use or medical application

The nausea peaks during weeks 6-8 and typically resolves by week 12 as the body adapts

GLP-1 medications have become one of the most talked-about treatments for weight management and type 2 diabetes

It works by inhibiting an enzyme called tyrosinase, which is involved in the production of melanin (skin pigment)

[1] [3] This distinguishes semaglutide from some medications that may contribute to dry mouth, such as SGLT2 inhibitors (which can cause dehydration through increased urination) or anticholinergic medications (which directly reduce salivary flow)